|Home | About | Journals | Submit | Contact Us | Français|
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|Study||Year||Size||Patient population||Type of study||Treatment||Duration of Rx (days)||Outcome|
|Dattwyler ||1988||23||Late Lyme disease in the NorthEast (NE) USA||Randomized trial||IV Ceftriaxone vs IV penicillin||14 vs 10||92% responded to ceftriaxone, 50% improved with penicillin|
|Logigian ||1990||27||Neurologic LD patients in NE USA||Case series||IV Ceftriaxone||14||63% improved, 22% improved but then relapsed, and 15% had no change in their condition|
|Hassler ||1990||135||Stage three borreliosis manifestations of at least six months' duration in Germany||Randomized trial||IV Cefotaxime vs IV penicillin G||10||87.9% vs 61.3% respectively Full or incomplete remission of symptoms in.|
|Wahlberg ||1994||100||Consecutive LD patients in Finland||Case series||IV Ceftriaxone, oral amoxicillin plus probenecid and/or oral cefhadroxil.*||14 to114||31% of 13 treatments successful with 14 days of IV ceftriaxone alone, 89% of 56 treatments with IV ceftriaxone followed by 100 days of amoxycillin plus probenecid successful, and 83% of 23 treatments with ceftriaxone followed by 100 days of cephadroxil successful.|
|Donta ||1997||277||Chronic LD in NE USA||Case series||Oral tetracycline||30 to 330||20% of the patients were cured; 70% of the patients' conditions improved.|
|Logigian ||1999||18||Neurologic LD in NE USA||Case series||IV ceftriaxone||28||100% of 18 patients rated themselves as back to normal or improved.|
|Klempner ||2001||107||LD with persistent symptoms in NE USA||Randomized trial||IV ceftriaxone + oral doxycycline||90||40% vs 36% for treatment vs placebo in improvement in quality of life (SF-36)|
|Krupp ||2003||55||LD with disabling fatigue in NE USA||Randomized trial||IV ceftriaxone||30||69% rx vs 23% for treatment vs placebo in the primary outcome – fatigue. No improvement on cognitive function or the clearance of Borrelia OspA antigen in the spinal fluid|
|Donta ||2003||235||LD with fatigue, musculoskeletal pain, and neurocognitive dysfunction in NE USA||Case series||Oral macrolide + hydroxychloroquine||90||80% had self reported improvements of 50% or more|
|Dattwyler ||2005||201||Late LD in NE USA||Randomized trial||IV ceftriaxone||14 vs. 28||76% vs 70% clinical cure rates for 14 and 28 days respectively|
|Borg ||2005||65||Neurologic LD in Sweden||Randomized trial||IV ceftriaxone vs oral doxycycline||10 to 14||79% vs 72% completely recovered, the remaining improved.|
* Patients treated with different combinations of oral, IM or IV antibiotics and variable durations of treatment.